Versor Investments LP Purchases New Holdings in Evolus, Inc. $EOLS

Versor Investments LP purchased a new stake in Evolus, Inc. (NASDAQ:EOLS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 11,049 shares of the company’s stock, valued at approximately $102,000.

Several other institutional investors also recently modified their holdings of the company. Pinnacle Associates Ltd. bought a new stake in shares of Evolus during the second quarter valued at approximately $6,318,000. Y Intercept Hong Kong Ltd boosted its stake in Evolus by 594.5% during the second quarter. Y Intercept Hong Kong Ltd now owns 259,487 shares of the company’s stock worth $2,390,000 after buying an additional 222,126 shares in the last quarter. AlphaQuest LLC increased its holdings in Evolus by 229.7% in the 2nd quarter. AlphaQuest LLC now owns 10,706 shares of the company’s stock valued at $99,000 after buying an additional 7,459 shares during the period. Bender Robert & Associates acquired a new position in shares of Evolus in the 2nd quarter valued at $231,000. Finally, Rhumbline Advisers lifted its holdings in shares of Evolus by 4.1% during the 1st quarter. Rhumbline Advisers now owns 83,436 shares of the company’s stock worth $1,004,000 after acquiring an additional 3,287 shares during the period. Institutional investors and hedge funds own 90.69% of the company’s stock.

Insider Transactions at Evolus

In related news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of Evolus stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $7.51, for a total value of $42,972.22. Following the completion of the transaction, the chief marketing officer directly owned 89,949 shares of the company’s stock, valued at $675,516.99. The trade was a 5.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Brady Stewart acquired 30,000 shares of the firm’s stock in a transaction on Friday, August 15th. The shares were bought at an average cost of $6.82 per share, for a total transaction of $204,600.00. Following the acquisition, the director owned 88,629 shares in the company, valued at approximately $604,449.78. The trade was a 51.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 5.90% of the company’s stock.

Evolus Stock Performance

Shares of EOLS opened at $6.56 on Friday. The company has a market cap of $425.22 million, a price-to-earnings ratio of -7.13 and a beta of 0.97. The stock has a fifty day moving average price of $6.67 and a two-hundred day moving average price of $8.37. Evolus, Inc. has a 52-week low of $5.71 and a 52-week high of $17.12.

Analyst Ratings Changes

EOLS has been the topic of a number of analyst reports. Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a research note on Saturday. BTIG Research reiterated a “buy” rating and issued a $18.00 price objective on shares of Evolus in a research note on Monday, September 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a research report on Wednesday. Needham & Company LLC reaffirmed a “hold” rating and issued a $22.00 price target on shares of Evolus in a research note on Wednesday, August 6th. Finally, HC Wainwright dropped their price objective on Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Evolus currently has an average rating of “Hold” and a consensus target price of $21.25.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.